Skip to main content

Table 2 Baselinea demographics and disease characteristics

From: Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study

 

All patients, N = 24

Sex, n (%)

 Female

15 (62.5)

 Male

9 (37.5)

Age, median (range), years

65.5 (57–90)

Age group, n (%), years

 < 65

11 (45.8)

 ≥ 65

13 (54.2)

Race, n (%)b

 Asian

1 (4.2)

 White

23 (95.8)

Weight, median (range), kg

69.5 (45–113)

BMI, median (range), kg/m2

25.3 (17.4–36.5)

Smoking history, n (%)

 Never

12 (50.0)

 Current

4 (16.7)

 Former

8 (33.3)

ESR, median (range), mm/h

4.0 (0–25)

CRP, median (range), mg/L

0.20 (0.20–5.81)

Duration of GCA, median (range), years

2.4 (0.8–13.2)

Glucocorticoid use for GCA, n (%)

7 (29.2)

  1. BMI Body mass index, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, GCA Giant cell arteritis
  2. aBaseline is day 1 of period 1
  3. bSelf-reported